Pretransplant immune risk assessment
- 1 December 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 14 (6) , 650-655
Abstract
Despite the introduction of advanced immunosuppressive drug therapies, clinical and subclinical rejections still occur in many graft recipients with a negative impact on the long-term transplant outcome. The immunological status of the patients awaiting the transplantation is a key factor for these processes. Here we summarize the recent efforts to identify and develop biomarkers and functional assays that allow an individual pretransplant risk assessment. New sensitive techniques assessing T-cell memory and B-cell activation have been developed. Furthermore, the expression level of soluble and molecular markers reflecting the activation state of the immune system and donor graft intrinsic factors have been shown to influence graft outcome. A variety of parameters and assays that determine the pretransplant immune activation status has been developed. Some of these assays have already been used prospectively to define high-risk patients receiving advanced immunosuppressive induction therapy. However, the conflicting results obtained in different studies show that biomarker analysis and functional assays performance need to be further standardized and validated in large prospective trials before they can be routinely implemented into a pretransplant risk assessment. Subsequently, a combined effort to design pretransplant risk stratification algorithms should lead to personalized immunosuppressive treatment regimes and improved graft survival and long-term graft function.Keywords
This publication has 66 references indexed in Scilit:
- Expression of Complement Components Differs Between Kidney Allografts from Living and Deceased DonorsJournal of the American Society of Nephrology, 2009
- Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevantHuman Immunology, 2009
- Activated Effector and Memory T Cells Contribute to Circulating sCD30: Potential Marker for Islet Allograft RejectionAmerican Journal of Transplantation, 2008
- Autoimmunity and transplantation: a meeting at the crossroads in BerlinNature Immunology, 2008
- Graft-derived complement as a mediator of transplant injuryCurrent Opinion in Immunology, 2007
- Low Pretransplantation Mannose-Binding Lectin Levels Predict Superior Patient and Graft Survival after Simultaneous Pancreas-Kidney TransplantationJournal of the American Society of Nephrology, 2007
- Association of Elevated Pretransplant sCD30 Levels With Graft Loss in 206 Patients Treated With Modern Immunosuppressive Therapies After Renal TransplantationTransplantation, 2007
- Establishing pediatric immune response zones using the Cylex® ImmuKnowTM assayClinical Transplantation, 2005
- T‐cell flow‐cytometry crossmatch and long‐term renal graft survivalClinical Transplantation, 2004
- Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidneyKidney International, 2004